Proteins in peril

Published By Datamonitor

Pharmacogenomics: the only thing to fear is fear itself

Revenue opportunities are going begging because of the pharmaceutical industry's reluctance to invest in pharmacogenomics, according to new research. Lower clinical development costs and promotional expenses could see opportunities in smaller markets increase dramatically, with pharmacogenomics-based diagnostics forcing companies to re-evaluate their R&D planning.

Published By Datamonitor

Pharmacia: seeking to deCODE pharmacogenomics

Pharmacia has followed Roche's example in teaming up with deCODE, in a deal that confirms Pharmacia's developing focus on the potential of pharmacogenomics. The company's many alliances in the field should help it launch new genomics-derived drugs, as well as cutting development costs and improving patient targeting.

Published By Datamonitor

Pharmaceutical Licensing Weekly Review: September 2 - 6, 2002

The week's licensing news has seen pharmaceutical companies becoming involved in agreements across the world. Atrix entered into a licensing deal with Key Oncologics relating to cancer treatments in South Africa whilst Schering-Plough signed a marketing agreement with Shionogi & Co in Japan. In America meanwhile, Enanta and Chiron formed an R&D collaboration as did Aventis and Astex Technology.

Published By Datamonitor

Novuspharma: lending a hand to Micromet

Novuspharma has agreed to co-develop Micromet's MT201, the only fully human antibody in development that targets the Ep-CAM molecule. The companies plan to begin phase II trials for the drug, across a wide range of cancers. Novuspharma's expertise and experience in oncology will aid MT201's development, but the companies will also need an experienced marketing partner.

Published By Datamonitor

Needless needles new technologies for vaccine delivery

Published By Datamonitor

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor

Millennium Pharma: 'Diagnomics' for melanoma

Published By Datamonitor

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor

Labeling versus drugs in tackling food allergies

Food allergies were first reported 100 years ago, and their reported incidence has been increasing dramatically over the last twenty years. However, food allergy is still an under-researched area, with no curative treatments in the drug pipeline. But is it worth investing in pharmaceutical therapies for food allergy, or will preventative measures work just as well?<BR />

Published By Datamonitor